183 related articles for article (PubMed ID: 21109988)
1. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
Indrová M; Símová J; Bieblová J; Bubeník J; Reinis M
Oncol Rep; 2011 Jan; 25(1):281-8. PubMed ID: 21109988
[TBL] [Abstract][Full Text] [Related]
2. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
3. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Pribylová H; Moravcová S; Jandlová T; Bubeník J
Int J Oncol; 2007 Apr; 30(4):1011-7. PubMed ID: 17332942
[TBL] [Abstract][Full Text] [Related]
4. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
Schroten C; Scheffer R; Boon L; de Ridder CM; Bangma CH; Kraaij R
J Immunother; 2012; 35(2):125-30. PubMed ID: 22306900
[TBL] [Abstract][Full Text] [Related]
5. IL-7 up-regulates IL-4 production by splenic NK1.1+ and NK1.1- MHC class I-like/CD1-dependent CD4+ T cells.
Hameg A; Gouarin C; Gombert JM; Hong S; Van Kaer L; Bach JF; Herbelin A
J Immunol; 1999 Jun; 162(12):7067-74. PubMed ID: 10358149
[TBL] [Abstract][Full Text] [Related]
6. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population.
von der Weid T; Beebe AM; Roopenian DC; Coffman RL
J Immunol; 1996 Nov; 157(10):4421-7. PubMed ID: 8906817
[TBL] [Abstract][Full Text] [Related]
7. The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation.
Shibolet O; Alper R; Zolotarov L; Trop S; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Clin Immunol; 2004 Apr; 111(1):82-92. PubMed ID: 15093555
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses.
Wang M; Ellison CA; Gartner JG; HayGlass KT
J Immunol; 1998 Feb; 160(3):1098-105. PubMed ID: 9570522
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
11. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
[TBL] [Abstract][Full Text] [Related]
13. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of Ly49 expression on CD4+ and CD4-CD8- (double negative) NK1.1+ T cells.
Sköld M; Cardell S
Eur J Immunol; 2000 Sep; 30(9):2488-96. PubMed ID: 11009081
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
16. Gamma delta T cells in the pathobiology of murine acute graft-versus-host disease. Evidence that gamma delta T cells mediate natural killer-like cytotoxicity in the host and that elimination of these cells from donors significantly reduces mortality.
Ellison CA; MacDonald GC; Rector ES; Gartner JG
J Immunol; 1995 Nov; 155(9):4189-98. PubMed ID: 7594574
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
18. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
19. Host MHC class I molecules modulate in vivo expression of a NK cell receptor.
Karlhofer FM; Hunziker R; Reichlin A; Margulies DH; Yokoyama WM
J Immunol; 1994 Sep; 153(6):2407-16. PubMed ID: 8077656
[TBL] [Abstract][Full Text] [Related]
20. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
